S. 5265 · 119th Congress · Foreign Trade and International Finance

USTRx Act

In committee924 words Introduced Aug 5, 2026 · Latest action Aug 5, 2026

How far it has goneStage 2 of 6
  1. IntroducedAug 5, 2026 Done
  2. CommitteeReferred to Finance Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

Congressional Research Service · summary of “Introduced in Senate” version · Aug 5, 2026

Who lobbies on it

1 organization · 1 filing · Q3 2026

See which of this bill’s sponsors and cosponsors got money from Pharmaceutical Research and Manufacturers of America’s PAC → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 1 of 1 quarter
    “…S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering…”

    $26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing

Organizations that named S. 5265 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Aug 5, 2026Read twice and referred to the Committee on Finance.
  2. Aug 5, 2026Introduced in Senate